Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Xilio Therapeutics Inc (NASDAQ: XLO) closed at $0.65 down -4.57% from its previous closing price of $0.68. In other words, the price has decreased by -$4.57 from its previous closing price. On the day, 1.44 million shares were traded. XLO stock price reached its highest trading level at $0.6977 during the session, while it also had its lowest trading level at $0.638.
Ratios:
For a deeper understanding of Xilio Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.20 and its Current Ratio is at 2.20.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on August 06, 2025, initiated with a Outperform rating and assigned the stock a target price of $2.
On December 21, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $7.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.H.C. Wainwright initiated its Buy rating on January 10, 2022, with a $36 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 16 ’25 when Shannon James Samuel bought 45,000 shares for $0.69 per share. The transaction valued at 30,870 led to the insider holds 45,000 shares of the business.
Shannon James Samuel bought 25,000 shares of XLO for $17,215 on Jun 17 ’25. The Director now owns 70,000 shares after completing the transaction at $0.69 per share. On Jun 16 ’25, another insider, Russo Rene, who serves as the PRESIDENT AND CEO of the company, bought 36,289 shares for $0.68 each. As a result, the insider paid 24,680 and bolstered with 281,172 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XLO now has a Market Capitalization of 34125212 and an Enterprise Value of -62375788. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.07. Its current Enterprise Value per Revenue stands at -1.961 whereas that against EBITDA is 1.479.
Stock Price History:
The Beta on a monthly basis for XLO is -0.04, which has changed by -0.26537216 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, XLO has reached a high of $1.70, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -15.28%, while the 200-Day Moving Average is calculated to be -13.54%.
Shares Statistics:
For the past three months, XLO has traded an average of 626.20K shares per day and 674440 over the past ten days. A total of 51.83M shares are outstanding, with a floating share count of 23.06M. Insiders hold about 56.07% of the company’s shares, while institutions hold 16.33% stake in the company. Shares short for XLO as of 1764288000 were 6675820 with a Short Ratio of 10.66, compared to 1761868800 on 6156308. Therefore, it implies a Short% of Shares Outstanding of 6675820 and a Short% of Float of 18.360001.
Earnings Estimates
At present, 1.0 analysts are actively evaluating the performance of Xilio Therapeutics Inc (XLO) in the stock market.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.14 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.44 and -$0.44 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.18, with 1.0 analysts recommending between -$0.18 and -$0.18.
Revenue Estimates
A total of 1 analysts believe the company’s revenue will be $7.96M this quarter.It ranges from a high estimate of $7.96M to a low estimate of $7.96M. As of. The current estimate, Xilio Therapeutics Inc’s year-ago sales were $1.72MFor the next quarter, 1 analysts are estimating revenue of $6.9M. There is a high estimate of $6.9M for the next quarter, whereas the lowest estimate is $6.9M.
A total of 1 analysts have provided revenue estimates for XLO’s current fiscal year. The highest revenue estimate was $45.65M, while the lowest revenue estimate was $45.65M, resulting in an average revenue estimate of $45.65M. In the same quarter a year ago, actual revenue was $6.34MBased on 1 analysts’ estimates, the company’s revenue will be $81.75M in the next fiscal year. The high estimate is $81.75M and the low estimate is $81.75M.
